Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

PURPOSE: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bortezomib, has improved pharmacokinetics, pharmacodyn...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lee, Edmund C., Fitzgerald, Michael, Bannerman, Bret, Donelan, Jill, Bano, Kristen, Terkelsen, Jennifer, Bradley, Daniel P., Subakan, Ozlem, Silva, Matthew D., Liu, Ray, Pickard, Michael, Li, Zhi, Tayber, Olga, Li, Ping, Hales, Paul, Carsillo, Mary, Neppalli, Vishala T., Berger, Allison J., Kupperman, Erik, Manfredi, Mark, Bolen, Joseph B., Van Ness, Brian, Janz, Siegfried
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3443972/
https://ncbi.nlm.nih.gov/pubmed/21903769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0636
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados